Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04250337 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
A Phase 3 study of Atopic Dermatitis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 228
- Enrollment target
- 20
- Study locations
NCT04250337: Completed Phase 3 study of Atopic Dermatitis, sponsored by Eli Lilly and Company.
NCT04250337 is a Phase 3 study of Atopic Dermatitis that has completed, run by Eli Lilly and Company. The registered enrollment target is 228 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04250337, a Phase 3 study of Atopic Dermatitis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 228 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.
Primary Outcome
The IGA measures the investigator's global assessment of the participant's overall severity of their AD, based on a static, numeric 5-point scale from 0 (clear skin) to 4 (severe disease). The score is based on an overall assessment of the degree of erythema, papulation/induration, oozing/crusting, and lichenification.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Lebrikizumab
- OTHER Topical Corticosteroid
Study Locations (20)
California
- Orange County Research Institute - Anaheim
- Bakersfield Dermatology and Skin Cancer Medical Group - Bakersfield
- Wallace Medical Group, Inc. - Beverly Hills
- First OC Dermatology - Fountain Valley
- Center For Dermatology Clinical Research, Inc. - Fremont
- California Allergy and Asthma Medical Group + Research Center - Los Angeles
- Keck School of Medicine University of Southern California - Los Angeles
- Dermatology Research Associates - Los Angeles
- LA Universal Research Center, INC - Los Angeles
- ACRC Studies - San Diego
- University Clinical Trials, Inc. - San Diego
- Southern California Dermatology, Inc. - Santa Ana
Florida
- St. Francis Medical Institute - Clearwater
- University of Florida - Gainesville - Gainesville
- Direct Helpers Medical Center - Hialeah
- The Community Research of South Florida - Hialeah
- GSI Clinical Research, LLC - Margate
- Vitae Research Center, LLC - Miami
Arizona
- Investigate MD - Scottsdale
District of Columbia
- Foxhall Dermatology - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2020-02-03 |
| Est. Completion | 2021-09-16 |
| Phase | Phase 3 |
What the finished NCT04250337 record still lists
NCT04250337 is an interventional study that assigns participants to a tested intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04250337 names 20 study sites across 4 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04250337 about?
NCT04250337 is a clinical study titled "Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.". This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS tre...
What is the current status of trial NCT04250337?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 228 participants. The study started on 2020-02-03. Estimated completion is 2021-09-16.
What conditions does trial NCT04250337 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT04250337?
The interventions under investigation include: Placebo (OTHER), Lebrikizumab (BIOLOGICAL), Topical Corticosteroid (OTHER).
Who is sponsoring clinical trial NCT04250337?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04250337 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04250337's enrollment target sits among peer trials
228 50th of 150 higher than 101 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI